HIV infection and cardiovascular pathology

According to modern literature data, the role of human immunodeficiency virus (HIV) infection has been proven as an independent risk factor (RF) for atherosclerosis and cardiovascular diseases (CVDs), including coronary artery disease, heart failure, and sudden cardiac death. The role of antiretroviral therapy (ART) in the occurrence of CVD remains debatable. On the one hand, ART is a mandatory component in CVD prevention, since there are numerous confirmations of the association of high viral load and noncompensated immune status with an increased risk of CVD. On the other hand, the use of certain classes of ART agents is associated with the development of dyslipidemia, insulin resistance, and type 2 diabetes, which are risk factors for CVD. In this regard, the current HIV treatment protocols require an assessment of CVD risk factors to select the optimal ART regimen. It must be remembered that when using generally accepted algorithms and scales for assessing the risk of CVD, the real risk may remain underestimated in HIV-infected patients. This literature review presents a patient data management algorithm developed by the American Heart Association and describes statin therapy in patients with HIV infection.

[1]  N. Koziolova,et al.  Contribution of inflammation to heart failure development in human immunodeficiency virus-infected patients , 2022, Russian Journal of Cardiology.

[2]  Arjun Sinha,et al.  Epidemiology, pathophysiology, and prevention of heart failure in people with HIV. , 2020, Progress in cardiovascular diseases.

[3]  Н. А. Козиолова,et al.  Особенности формирования хронической сердечной недостаточности у больных, инфицированных вирусом иммунодефицита человека , 2020 .

[4]  D. Duplyakov,et al.  Coronary Heart Disease in HIV-Infected Patients , 2020, Rational Pharmacotherapy in Cardiology.

[5]  Steven C. Johnson,et al.  Examining Mortality To Identify Opportunities for Improved Care Among Adults with HIV in a Single Academic Medical Center. , 2019, AIDS research and human retroviruses.

[6]  T. Neilan,et al.  Heart Failure among People with HIV: Evolving Risks, Mechanisms, and Preventive Considerations , 2019, Current HIV/AIDS Reports.

[7]  M. Budoff,et al.  HIV Infection Is Associated with Greater Left Ventricular Mass in the Multicenter AIDS Cohort Study. , 2019, AIDS Research and Human Retroviruses.

[8]  D. Lloyd‐Jones,et al.  Ventricular Ectopy and Arrhythmia Characteristics for Persons Living with HIV and Uninfected Controls , 2019, Journal of the International Association of Providers of AIDS Care.

[9]  R. Greenblatt,et al.  HIV infection is an independent risk factor for decreased 6-minute walk test distance , 2019, PloS one.

[10]  S. Cyr,et al.  Mechanisms of Arrhythmia and Sudden Cardiac Death in Patients With HIV Infection. , 2019, The Canadian journal of cardiology.

[11]  F. Violi,et al.  Atrial fibrillation and human immunodeficiency virus type‐1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy , 2019, British journal of clinical pharmacology.

[12]  Н. А. Козиолова,et al.  ВИЧ-АССОЦИИРОВАННАЯ ПАТОЛОГИЯ СЕРДЕЧНО-СОСУДИСТОЙ СИСТЕМЫ , 2019 .

[13]  A. Mocumbi,et al.  Need for active cardiovascular screening in HIV-infected children under antiretroviral therapy in Africa. , 2019, Cardiovascular diagnosis and therapy.

[14]  H. Bang,et al.  Prolonged QTc in HIV-Infected Patients: A Need for Routine ECG Screening , 2019, Journal of the International Association of Providers of AIDS Care.

[15]  Katherine C. Wu,et al.  Predictors of electrocardiographic QT interval prolongation in men with HIV , 2018, Heart.

[16]  T. Neilan,et al.  Protease Inhibitors and Cardiovascular Outcomes in Patients With HIV and Heart Failure. , 2018, Journal of the American College of Cardiology.

[17]  Yanan Jiang,et al.  The role of HIV Tat protein in HIV-related cardiovascular diseases , 2018, Journal of Translational Medicine.

[18]  D. Lloyd‐Jones,et al.  Atrial arrhythmia prevalence and characteristics for human immunodeficiency virus-infected persons and matched uninfected controls , 2018, PloS one.

[19]  S. Colan,et al.  Cardiac Effects of Highly Active Antiretroviral Therapy in Perinatally HIV-Infected Children: The CHAART-2 Study. , 2017, Journal of the American College of Cardiology.

[20]  G. d’Ettorre,et al.  Cardiovascular risk and dyslipidemia among persons living with HIV: a review , 2017, BMC Infectious Diseases.

[21]  Xinguang Chen,et al.  Global prevalence of hypertension among people living with HIV: a systematic review and meta-analysis. , 2017, Journal of the American Society of Hypertension : JASH.

[22]  Olga V. Patterson,et al.  Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era: Results From the Veterans Aging Cohort Study , 2017, JAMA cardiology.

[23]  J. C. A. Lacson,et al.  HIV Infection and Risk of Cardiovascular Diseases Beyond Coronary Artery Disease , 2017, Current Atherosclerosis Reports.

[24]  E. Wing HIV and aging. , 2016, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[25]  A. Lonardo,et al.  Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV , 2016, World journal of gastroenterology.

[26]  U. Hoffmann,et al.  HIV Infection and Heart Failure Outcomes in Women. , 2016, Journal of the American College of Cardiology.

[27]  E. Bahiru,et al.  Patterns of Cardiovascular Mortality for HIV-Infected Adults in the United States: 1999 to 2013. , 2016, The American journal of cardiology.

[28]  M. Myerson,et al.  Management of lipid disorders in patients living with HIV , 2015, Journal of clinical pharmacology.

[29]  G. Adler,et al.  RAAS Activation Is Associated With Visceral Adiposity and Insulin Resistance Among HIV-infected Patients. , 2015, The Journal of clinical endocrinology and metabolism.

[30]  D. Lloyd‐Jones,et al.  A Systematic Review of the Usefulness of Statin Therapy in HIV-Infected Patients. , 2015, The American journal of cardiology.

[31]  B. Nordestgaard,et al.  Myocardial infarction among Danish HIV-infected individuals: population-attributable fractions associated with smoking. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  K. Sliwa,et al.  HIV and the heart: the impact of antiretroviral therapy: a global perspective. , 2013, European heart journal.

[33]  F. Gaita,et al.  Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. , 2013, European heart journal.

[34]  E. Vittinghoff,et al.  Sudden cardiac death in patients with human immunodeficiency virus infection. , 2012, Journal of the American College of Cardiology.

[35]  F. Gaita,et al.  Coronary artery disease Acute coronary syndromes in human immunodeficiency virus patients : a meta-analysis investigating adverse event rates and the role of antiretroviral therapy , 2012 .

[36]  E. Soliman,et al.  Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: results from the Strategies for Management of Antiretroviral Therapy study. , 2011, Journal of electrocardiology.

[37]  De-Li Dong,et al.  HIV Tat protein inhibits hERG K+ channels: a potential mechanism of HIV infection induced LQTs. , 2011, Journal of molecular and cellular cardiology.

[38]  L. Kuller,et al.  Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. , 2011, Archives of internal medicine.

[39]  D. Jacobs,et al.  Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. , 2010, The Journal of infectious diseases.

[40]  A. Barbagelata,et al.  Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem , 2009, Current cardiology reviews.

[41]  Lewis H Kuller,et al.  Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection , 2008, PLoS medicine.

[42]  Hang Lee,et al.  Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. , 2007, The Journal of clinical endocrinology and metabolism.

[43]  John T Brooks,et al.  Mortality in the Highly Active Antiretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study , 2006, Journal of acquired immune deficiency syndromes.

[44]  R. Pandey,et al.  Cardiac dysfunction in human immunodeficiency virus (HIV) infected patients in India. , 2006, International journal of cardiology.

[45]  M. Bukrinsky,et al.  Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion- and death receptor-controlled pathways , 2002, Proceedings of the National Academy of Sciences of the United States of America.